EUCTR2013-003075-35-CZ进行中（未招募）1 期
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination fluticasone furoate/ umeclidinium/vilanterol, with the fixed dose dual combinations of fluticasone furoate/vilanterol and umeclidinium/vilanterol, all administered once-daily in the morning via a dry powder inhalerin subjects with chronic obstructive pulmonary disease - 12m, Phase III, FF/UMEC/VI vs FF/VI and UMEC/VI COPD exacerbation trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed Consent: A signed and dated written informed consent prior to study participation.
- •2. Type of subject: Outpatient.
- •3. Age: Subjects 40 years of age or older at Visit 1.
- •4. Gender: Male or female subjects.
- •A female is eligible to enter and participate in the study if she is of:
- •Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy.
- •Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study – screening to safety follow-up contact):
- •- Abstinence
- •- Oral Contraceptive, either combined or progestogen alone
- •- Injectable progestogen
- •- Implants of levonorgestrel
- •- Estrogenic vaginal ring
- •- Percutaneous contraceptive patches
- •- Intrauterine device (IUD) or intrauterine system (IUS)
- •- Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, documented” refers to the outcome of the investigator's/designee’s medical examination of the subject
- •or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records.
- •- Double barrier method: condom and an occlusive cap (diaphragm or
- •cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
- •5. COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004].
- •6. Smoking History: Current or former cigarette smokers with a history of cigarette smoking of =10 pack-years at screening (visit 1) [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or
- •cigar use cannot be used to calculate pack-year history
- •7. Severity of COPD symptoms: A score of =10 on the COPD Assessment Test (CAT) at screening.
- •8. Severity of COPD Disease: A post-albuterol/salbutamol FEV1/FVC ratio of <0.70 at Screening.
- •9. Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only PRN COPD medications are not eligible.
- •10. History of Exacerbations: Subjects must demonstrate:
- •a post-bronchodilator FEV1 < 50% predicted normal and a documented history of = 1 moderate or severe COPD exacerbation in the previous 12 months
- •a post-bronchodilator 50% =FEV1 < 80% predicted normal and a documented history of = 2 moderate exacerbations or a documented history of =1 severe COPD exacerbation (hospitalized) in the previous 12 months.
- •Note: Percent predicted will be cal
排除标准
- •1. Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- •2. Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD).
- •3. a1-antitrypsin deficiency: Subjects with a1-antitrypsin deficiency as the underlying cause of COPD.
- •4. Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.
- •5. Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening.
- •6. Risk Factors for Pneumonia: immune suppression (e.g. HIV, Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson’s Disease, Myasthenia Gravis) Patients at potentially high risk (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator.
- •7. Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded.
- •8. Other Respiratory tract infections that have not resolved at least 7 days prior to screening.
- •9. Abnormal Chest x-ray: Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All
- •subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or CT scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post
- •pneumonia/exacerbation chest x-ray to be over-read by the central vendor or have a chest x-ray conducted at screening.
- •For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (BfS).
- •10. Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any
- •disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
- •11. Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert’s
- •syndrome or asymptomatic gallstones). Note: Chronic stable hepatitis B and C are
研究者
相似试验
进行中（未招募）
1 期
A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2013-003075-35-PLGlaxoSmithKline Research & Development Ltd10,000
已完成
3 期
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary diseaseCOPDchronic obstructive pulmonary disease10038716NL-OMON45240GlaxoSmithKline225
进行中（未招募）
1 期
A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 19.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2013-003075-35-DEGlaxoSmithKline Research & Development Ltd10,000
进行中（未招募）
1 期
A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 17.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2013-003075-35-NOGlaxoSmithKline Research & Development Ltd13,905
进行中（未招募）
1 期
A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2013-003075-35-BEGlaxoSmithKline Research & Development Ltd10,000